首页> 外文期刊>Health policy >Systematic review of the methodological quality of clinical guideline development for the management of chronic disease in Europe
【24h】

Systematic review of the methodological quality of clinical guideline development for the management of chronic disease in Europe

机译:对欧洲慢性疾病管理临床指南制定方法学质量的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The use of evidence-based clinical guidelines is an essential component of chronic disease management. However, there is well-documented concern about variability in the quality of clinical guidelines, with evidence of persisting methodological shortcomings. The most widely accepted approach to assessing the quality of guidelines is the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument. We have conducted a systematic review of the methodological quality (as assessed by AGREE) of clinical guidelines developed in Europe for the management of chronic diseases published since 2000. Methods: The systematic review was undertaken in accordance with the Cochrane methodology. The inclusion criteria were that studies should have appraised European clinical guidelines for certain selected chronic disorders using the AGREE instrument. We searched five databases (Cab Abstracts, EMBASE, MEDLINE, Trip and EPPI). Results: Nine studies reported in 10 papers, analysing a total of 28 European guidelines from eight countries as well as pan-European, were included. There was considerable variation in the quality of clinical guidelines across the AGREE domains. The least well addressed domains were 'editorial independence' (with a mean domain score of 41%), 'applicability' (44%), 'stakeholder involvement' (55%), and 'rigour of development' (64%), while 'clarity of presentation' (80%) and 'scope and purpose' (84%) were less problematic. Conclusion: This review indicates that there is considerable scope for improvement in the methods used to develop clinical guidelines for the prevention, management and treatment of chronic diseases in Europe. Given the importance of decision support strategies such as clinical guidelines in chronic disease management, improvement measures should include the explicit and transparent involvement of key stakeholders (especially scientific experts, guideline users and methodological specialists) and consideration of the implications for guideline implementation and applicability early on in the process.
机译:简介:使用循证临床指南是慢性疾病管理的重要组成部分。但是,关于临床指南质量变化的证据已得到充分关注,并存在持续存在的方法学缺陷。评估指南质量的最广泛接受的方法是研究与评估指南评估(AGREE)仪器。自2000年以来,我们对欧洲制定的用于管理慢性病的临床指南的方法学质量(通过AGREE进行了评估)进行了系统的综述。方法:系统评价是根据Cochrane方法进行的。纳入标准是研究应使用AGREE仪器评估某些选定的慢性疾病的欧洲临床指南。我们搜索了五个数据库(Cab Abstracts,EMBASE,MEDLINE,Trip和EPPI)。结果:包括10篇论文中的9项研究,分析了来自8个国家和整个欧洲国家的28项欧洲指南。跨AGREE领域的临床指南质量存在很大差异。处理最不完善的领域是“版本独立性”(平均领域得分为41%),“适用性”(44%),“利益相关者的参与”(55%)和“发展的严谨性”(64%),而“陈述的清晰性”(80%)和“范围和目的”(84%)的问题较少。结论:这项审查表明,在欧洲制定预防,管理和治疗慢性疾病的临床指南的方法上,有很大的改进空间。鉴于诸如临床指南等决策支持策略在慢性病管理中的重要性,改善措施应包括关键利益相关者(尤其是科学专家,指南使用者和方法专家)的明确透明参与,并尽早考虑对指南实施和适用性的影响在此过程中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号